hs-CRP: Which Tests to Order Alongside It

What hs-CRP Actually Measures

Hs-CRP is the same protein as standard CRP, measured with a high-sensitivity assay that detects concentrations as low as 0.1 mg/L rather than the 3 to 5 mg/L floor of a routine CRP. This precision matters because the cardiovascular and metabolic risk signal lives entirely in the 0.5 to 10 mg/L range, a zone that standard CRP misses entirely.

CRP is synthesized by the liver in response to interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) released from adipose tissue, atherosclerotic plaques, and visceral fat depots. Persistently elevated hs-CRP therefore reflects ongoing, low-grade vascular and metabolic inflammation rather than acute injury.

Biological Origin and What Drives It Up

Adipose tissue is the dominant driver of chronically elevated hs-CRP in metabolically unhealthy individuals. A 2003 analysis published in Circulation confirmed that visceral adiposity independently predicts hs-CRP elevation after adjustment for BMI, fasting glucose, and lipids. [1]

Smoking, physical inactivity, periodontal disease, obstructive sleep apnea, and hypertension each add independent hs-CRP burden. In clinical practice, an hs-CRP above 10 mg/L almost always signals an acute-phase response from infection, autoimmune flare, or tissue injury, and the result should be discarded for cardiovascular risk purposes. Repeat testing 2 to 3 weeks after resolution is standard.

Why Standard CRP Is Not a Substitute

Standard CRP assays report results in whole-number increments and cannot reliably distinguish a value of 0.8 mg/L from 2.9 mg/L. Both fall below the detection floor and return as "normal." The hs-CRP assay resolves this range with precision to one decimal place, which is why the ACC/AHA 2019 guideline on primary prevention specifically names hs-CRP, not standard CRP, as a risk-enhancing factor in the 7.5 to 20% 10-year ASCVD risk tier. [2]

Normal hs-CRP Range and What Results Mean

The American Heart Association and CDC issued a joint scientific statement establishing three cardiovascular risk categories based on hs-CRP. [3]

| hs-CRP (mg/L) | Cardiovascular Risk Category | |---|---| | <1.0 | Low | | 1.0 to 3.0 | Intermediate | | >3.0 | High | | >10.0 | Probable acute inflammation, result not used for CV risk |

Intermediate Range: The Clinical Decision Zone

The 1.0 to 3.0 mg/L band is where hs-CRP does the most clinical work. Patients in this range are neither clearly low-risk nor obviously high-risk by lipid criteria alone. The JUPITER trial (N=17,802) demonstrated that rosuvastatin 20 mg/day reduced the rate of major cardiovascular events by 44% (hazard ratio 0.56, 95% CI 0.46 to 0.68, P<0.00001) in apparently healthy adults with LDL-C below 130 mg/dL but hs-CRP at or above 2.0 mg/L. [4] That trial result is the primary evidence base for the 2018 ACC/AHA cholesterol guideline's recommendation to consider hs-CRP when deciding whether to initiate statin therapy in borderline-risk patients. [5]

High and Very High Values

An hs-CRP consistently above 3.0 mg/L after ruling out acute infection signals excess cardiovascular risk independent of LDL-C. Values persistently above 5.0 mg/L in the absence of active illness should prompt evaluation for autoimmune disease, occult infection, obstructive sleep apnea, or severe insulin resistance.

The Core Paired-Test Panel

Ordering hs-CRP without context is like reading one vital sign in isolation. The following panel, built around primary guideline recommendations, converts hs-CRP from a single data point into a cardiovascular and metabolic risk story.

Fasting Lipid Panel and Apolipoprotein B

A standard fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides) pairs with hs-CRP because the two measure different biological pathways. LDL-C quantifies atherogenic particle burden by cholesterol mass; hs-CRP quantifies the vascular inflammatory response to that burden. Elevated hs-CRP with normal LDL-C is the exact scenario JUPITER studied, and it identifies a population that benefits from statin therapy despite appearing low-risk by LDL-C alone. [4]

Apolipoprotein B (ApoB) adds further precision. Each LDL, VLDL, IDL, and Lp(a) particle carries exactly one ApoB molecule, making ApoB a direct particle count that outperforms LDL-C for residual cardiovascular risk prediction. The 2019 ESC/EAS dyslipidemia guideline lists ApoB as the preferred secondary lipid target in patients with high triglycerides or metabolic syndrome, precisely the population in whom hs-CRP is also likely elevated. [6]

ApoB below 80 mg/dL correlates with optimal cardiovascular risk reduction in high-risk patients, per the Canadian Cardiovascular Society 2021 guidelines. Pairing ApoB with hs-CRP identifies patients who have both residual particle burden and active vascular inflammation, the highest-risk subgroup.

Fasting Insulin and HOMA-IR

Insulin resistance drives hs-CRP elevation through IL-6 secretion from adipose tissue. A fasting insulin level combined with fasting glucose allows calculation of HOMA-IR (homeostatic model assessment of insulin resistance): HOMA-IR = (fasting insulin mU/L × fasting glucose mmol/L) / 22.5. A HOMA-IR above 2.5 to 3.0 is widely used in research as an insulin resistance threshold, though the ADA notes the assay lacks full standardization. [7]

Pairing hs-CRP with fasting insulin is particularly valuable in patients with normal fasting glucose. Insulin resistance can exist for years before glucose rises above the prediabetes threshold of 100 mg/dL, and hs-CRP often elevates in parallel. A 2004 prospective analysis in Diabetes Care (N=2,693) found hs-CRP was significantly higher across successive HOMA-IR quartiles even after adjusting for BMI and waist circumference. [8]

Hemoglobin A1c

HbA1c reflects average blood glucose over roughly 90 days and flags prediabetes (5.7 to 6.4%) and type 2 diabetes (6.5% or above) per ADA 2024 standards. [9] Chronic hyperglycemia independently activates the same IL-6 and TNF-α pathways that drive hs-CRP elevation. An elevated hs-CRP alongside an HbA1c in the 5.7 to 6.4% range is a strong signal to initiate lifestyle intervention before glucose dysregulation progresses.

Homocysteine

Homocysteine is an independent cardiovascular risk marker whose mechanism involves direct endothelial toxicity and oxidative stress rather than the lipid-pathway mechanisms that LDL-C and ApoB measure. Optimal fasting homocysteine is below 10 µmol/L; levels above 15 µmol/L (hyperhomocysteinemia) are associated with a roughly 2-fold increase in cardiovascular event risk in observational data. [10]

Homocysteine and hs-CRP raise through partially distinct pathways, so they add independent information. Elevated homocysteine may respond to methylfolate (5-MTHF), B6, and B12 supplementation, especially in patients carrying MTHFR polymorphisms. Ordering both tests allows the clinician to separate inflammatory burden from methylation-pathway dysfunction.

Fibrinogen

Fibrinogen is a coagulation protein that doubles as an acute-phase reactant. Elevated fibrinogen predicts cardiovascular events independently of cholesterol, and it rises alongside hs-CRP during low-grade inflammation. The CDC/AHA 2003 statement on novel cardiovascular risk markers listed both hs-CRP and fibrinogen as having sufficient evidence for clinical use in primary prevention risk assessment. [3]

A fibrinogen above 350 to 400 mg/dL in a fasting, non-pregnant, non-acutely ill adult warrants clinical attention, particularly if hs-CRP is simultaneously elevated above 2.0 mg/L. The combination suggests persistent prothrombotic inflammation rather than a transient spike.

Lipoprotein(a)

Lp(a) is a genetically determined, largely fixed atherogenic lipoprotein that standard lipid panels do not measure. The European Atherosclerosis Society recommends measuring Lp(a) at least once in every adult's lifetime to stratify lifetime cardiovascular risk. [11] An Lp(a) above 50 mg/dL (or 125 nmol/L) places a patient in a higher risk tier regardless of LDL-C.

The rationale for pairing Lp(a) with hs-CRP is mechanistic: Lp(a) carries oxidized phospholipids that trigger vascular wall inflammation, which can contribute to hs-CRP elevation. Identifying both simultaneously explains why some patients have persistent hs-CRP elevation despite optimal LDL-C on statin therapy.

Thyroid-Stimulating Hormone

Hypothyroidism is a correctable cause of elevated hs-CRP, elevated LDL-C, and elevated homocysteine simultaneously. Even subclinical hypothyroidism (TSH 4.5 to 10 mIU/L with normal free T4) is associated with higher hs-CRP in cross-sectional data. [12] Including TSH in the initial paired panel ensures that a single treatable diagnosis is not missed when multiple inflammatory and lipid markers are out of range.

Additional Tests to Consider in Specific Clinical Contexts

The following tests are not universally required with every hs-CRP order but should be added when clinical context suggests specific mechanistic pathways.

Insulin-Like Growth Factor 1 (IGF-1)

Adult growth hormone deficiency and relative IGF-1 deficiency are associated with increased visceral adiposity and elevated hs-CRP. In patients on hormone optimization protocols, including testosterone replacement therapy (TRT) or growth hormone peptide therapy (e.g., tesamorelin or CJC-1295/ipamorelin), baseline and follow-up IGF-1 provides context for changes in inflammatory markers over time.

Sex Hormones: Total and Free Testosterone, Estradiol, SHBG

Low testosterone in men correlates with elevated hs-CRP in multiple observational studies. A 2010 cross-sectional analysis in European Journal of Endocrinology (N=2,009) reported that men in the lowest testosterone quartile had hs-CRP values approximately 40% higher than men in the highest quartile after adjusting for age, BMI, and smoking. [13] In women, estrogen decline at perimenopause is associated with rising hs-CRP, a finding consistent with estrogen's known anti-inflammatory vascular effects. [14]

Ordering sex hormones alongside hs-CRP is especially relevant in patients presenting with fatigue, reduced libido, or body composition changes, because correcting sex hormone deficiency may be both the cause of elevated hs-CRP and a direct therapeutic lever.

Uric Acid

Elevated uric acid (hyperuricemia, generally above 6.8 mg/dL in women and above 7.0 mg/dL in men) is associated with endothelial dysfunction and predicts cardiovascular events independently of traditional risk factors. Uric acid and hs-CRP co-raise in metabolic syndrome and gout. Adding a serum uric acid to the panel is inexpensive and guides both dietary and pharmacologic intervention.

Complete Blood Count with Differential

A CBC with differential is not a direct inflammation marker, but it screens for conditions that artificially raise hs-CRP, including occult infection, chronic anemia, and myeloproliferative disorders. Before attributing a persistently elevated hs-CRP to metabolic inflammation, a normal WBC count and differential help rule out hematologic contributors.

How to Lower hs-CRP: Evidence-Based Interventions

The most effective strategies for reducing hs-CRP target the upstream drivers of vascular and metabolic inflammation.

Statin Therapy

Statins reduce hs-CRP by 15 to 25% independent of their LDL-lowering effect. In JUPITER, rosuvastatin 20 mg reduced median hs-CRP from 4.2 mg/L at baseline to 2.2 mg/L at 12 months, a 37% reduction. [4] This pleiotropic anti-inflammatory effect is now cited in the 2019 ACC/AHA primary prevention guideline as part of the rationale for statin use in intermediate-risk patients with elevated hs-CRP. [2]

Weight Reduction

A 5 to 10% reduction in body weight produces meaningful hs-CRP reductions. In the STEP-1 trial (N=1,961), semaglutide 2.4 mg subcutaneously once weekly produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo. [15] Reductions in visceral adiposity, the dominant IL-6 source, drive the hs-CRP improvement.

Mediterranean and Anti-Inflammatory Diets

The PREDIMED trial (N=7,447) found that a Mediterranean diet supplemented with extra-virgin olive oil reduced hs-CRP levels significantly compared with a low-fat control diet over a median follow-up of 4.8 years (P<0.05 for between-group difference). [16] Replacing refined carbohydrates and trans fats with omega-3 fatty acids, polyphenols, and fiber is the dietary cornerstone of hs-CRP reduction.

Aerobic Exercise

A meta-analysis of 83 randomized controlled trials published in the European Journal of Preventive Cardiology (N=4,007) found that aerobic exercise training reduced hs-CRP by a weighted mean of 0.33 mg/L (95% CI 0.17 to 0.50, P<0.001). [17] The threshold dose appears to be at least 150 minutes per week of moderate-intensity activity, consistent with the 2018 Physical Activity Guidelines for Americans.

Omega-3 Fatty Acids

High-dose omega-3 supplementation (EPA/DHA at 3 to 4 g/day) reduces triglycerides and modestly lowers hs-CRP. The REDUCE-IT trial (N=8,179) demonstrated that icosapentaenoic acid (EPA) 4 g/day reduced cardiovascular events by 25% in statin-treated patients with elevated triglycerides, with reductions in inflammatory biomarkers including hs-CRP observed in the treatment arm. [18]

Monitoring Frequency and Pre-Analytic Considerations

When to Repeat hs-CRP

In stable patients being monitored for cardiovascular risk, repeat hs-CRP every 6 to 12 months alongside the lipid panel is reasonable. When a value exceeds 10 mg/L, repeating in 2 to 3 weeks after resolution of any suspected acute illness is standard practice before using the result for clinical decision-making.

Fasting and Timing

Hs-CRP does not require fasting. However, ordering it simultaneously with a fasting lipid panel and fasting insulin means the patient is typically fasting for the draw anyway, making coordination straightforward. Avoid ordering hs-CRP within 4 weeks of vaccination, major surgery, or documented infection, as all three trigger acute-phase responses that transiently raise the result.

Interfering Conditions

Pregnancy, oral contraceptive use (due to hepatic estrogen effects on CRP synthesis), and active autoimmune flare all raise hs-CRP through mechanisms unrelated to cardiovascular risk. Noting these on the lab requisition avoids misclassification.

Clinical Application: Putting the Panel Together

Ordering a full paired panel in a single fasting blood draw is practical and efficient. A reasonable baseline inflammatory and metabolic panel for a 40-year-old with no known cardiovascular disease but with central adiposity and family history might include:

1. Hs-CRP
2. Fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides)
3. ApoB
4. Fasting insulin and fasting glucose (for HOMA-IR calculation)
5. HbA1c
6. Homocysteine
7. Fibrinogen
8. Lp(a) (once-lifetime if not previously measured)
9. TSH
10. Uric acid
11. CBC with differential
12. Sex hormones (testosterone, estradiol, SHBG) if clinically indicated

The ACC/AHA 2019 guideline on primary prevention states: "If the decision to initiate statin therapy remains uncertain, measurement of hs-CRP, coronary artery calcium score, or ABI may be useful to guide decision-making." [2] This framing positions hs-CRP as a tie-breaker, not a standalone test, which is exactly why the paired panel matters.